Related Experiment Videos
Intravitreal triamcinolone for refractory pseudophakic macular edema
Nathanael Benhamou1, Pascale Massin, Belkacem Haouchine
1Department of Ophthalmology, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, Université Paris 7, Paris, France. nathanael_benhamou@yahoo.fr
American Journal of Ophthalmology
|February 5, 2003
Summary
Intravitreal triamcinolone temporarily reduced pseudophakic cystoid macular edema and improved vision. However, the beneficial effects were transient, with recurrence of macular edema observed within months, even after a second injection.
Area of Science:
- Ophthalmology
- Retinal Diseases
- Pharmacology
Background:
- Pseudophakic cystoid macular edema (CME) is a common complication after cataract surgery.
- Refractory CME poses a therapeutic challenge, often requiring advanced treatment modalities.
Purpose of the Study:
- To assess the efficacy of intravitreal triamcinolone acetonide in treating chronic, medication-refractory pseudophakic CME.
Main Methods:
- A prospective case series involving three patients with longstanding pseudophakic CME.
- Treatment involved an 8 mg intravitreal injection of triamcinolone acetonide.
- Patients were monitored using visual acuity charts, fluorescein angiography, and optical coherence tomography (OCT).
Main Results:
- OCT revealed significant reduction in macular thickness within one month post-injection (mean 502 to 233 microm).
- Mean visual acuity improved by 3.7 Snellen lines.
- Recurrence of CME and vision decrease occurred within 2-4 months in all patients, necessitating a second injection in two cases, which also yielded only transient results.
Conclusions:
- Intravitreal triamcinolone acetonide effectively induces short-term regression of chronic, refractory pseudophakic CME.
- The therapeutic benefits are temporary, with edema recurring even after repeat injections.